Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

HIV Medicine

Volumn 12, Issue 3, 2011, Pages 166-173

  Lambert, J S ^a,b,c   Else, L J ^d   Jackson, V ^a   Breiden, J ^b   Gibbons, S ^d   Dickinson, L ^d,e   Back, D J ^d   Brennan, M ^a   Connor, E O ^b   Boyle, N ^f   Fleming, C ^f   Coulter Smith, S ^a   Khoo, S H ^d  

^a ROTUNDA HOSPITAL   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Lopinavir; Pharmacokinetics; Pregnancy; Protein binding; Therapeutic drug monitoring

Indexed keywords

LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PREGNANCY; PRENATAL CARE; PRENATAL PERIOD; PRIORITY JOURNAL; PUERPERIUM; SECOND TRIMESTER PREGNANCY; TANDEM MASS SPECTROMETRY; THIRD TRIMESTER PREGNANCY; ULTRAFILTRATION; VIRUS LOAD; WILD TYPE;

ADULT; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMIDINONES; RITONAVIR; YOUNG ADULT;

EID: 79551605542     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00865.x     Document Type: Article

References (34)

1. de Ruiter A, Mercey D, Anderson J et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9: 452-502.
2. Perinatal HIV Guidelines Working Group. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Available at (updated 29th April 2009) (accessed 20 December 2009).
3. Stek AM, Mirochnick M, Capparelli E et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20: 1931-1939.
4. Aweeka F, Stek A, Best BM et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med 2009; 11: 232-238.
5. Peytavin G, Pierre-Francois S, Cassard B et al. Reduced lopinavir exposure during pregnancy: A case control study. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 579].
6. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 2007; 21: 643-645.
7. Mirochnick M, Best BM, Stek AM et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49: 485-491.
8. Gauthier J, Boucher M, Higgins N et al. Therapeutic drug monitoring of lopinavir/ritonavir (tablet formulation) in pregnancy. 10th International Workshop on the Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, April 2009 [Abstract P49].
9. Khuong-Josses MA, Azerad D, Boussairi A, Ekoukou D. Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women. HIV Clin Trials 2007; 8: 254-255.
10. Fayet A, Decosterd LA, Buclin T et al. Free and total pharmacokinetics of lopinavir (LPV), atazanavir (ATV) and nevirapine (NVP) during the course of pregnancy, in the umbilical cord and at post-partum. 10th International Workshop on the Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, April 2009 [Abstract P57].
11. Klein CE, Chiu YL, Awni W et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44: 401-410.
12. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther 1980; 10: 301-328.
13. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43: 1071-1087.
14. Boffito M, Back DJ, Blaschke TF et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19: 825-835.
15. Sparreboom A, Nooter K, Loos WJ, Verweij J. The (ir)relevance of plasma protein binding of anticancer drugs. Neth J Med 2001; 59: 196-207.
16. Stumpe M, Miller C, Morton NS et al. High-performance liquid chromatography determination of alpha1-acid glycoprotein in small volumes of plasma from neonates. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 831: 81-84.
17. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 1990; 18: 20-36.
18. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001; 33: 161-235.
19. Kiser J, Mawhinney S, Kinzie K et al. Total and unbound lopinavir/ritonavir pharmacokinetics in a concentration-guided study of HIV-infected women throughout pregnancy and post-partum. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 2009 [Abstract 946].
20. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-1465.
21. Droste JA, Aarnoutse RE, Koopmans PP et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-291.
22. Almond LM, Edirisinghe D, Dalton M et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 2005; 78: 132-142.
23. Boffito M, Hoggard PG, Reynolds HE et al. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. Br J Clin Pharmacol 2002; 54: 262-268.
24. Boffito M, Gatti G, Almond LM et al. Amprenavir protein binding in HIV-infected patients. 9th European AIDS Conference (EACS). Warsaw, Poland, October 2003 [Abstract 4.1].
25. Boffito M, Hoggard PG, Lindup WE et al. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit 2004; 26: 35-39.
26. Almond LM, Boffito M, Hoggard PG et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004; 20: 716-722.
27. Almond LM, Hoggard PG, Edirisinghe D et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-744.
28. La Porte CJL, Back DJ, Blaschke T et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy 2006; 3: 4-14.
29. Boffito M, Else L, Back D et al. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72h following drug cessation. Antivir Ther 2008; 13: 901-907.
30. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008; 3: 296-305.
31. Masquelier B, Breilh D, Neau D et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002; 46: 2926-2932.
32. Breilh D, Pellegrin I, Rouzes A et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004; 18: 1305-1310.
33. Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982; 7: 336-352.
34. Krauer B, Dayer P, Anner R. Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol 1984; 91: 875-881.